Blogs FGFRs in Disease and Drug Discovery

FGFRs in Disease and Drug Discovery

Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases (RTKs) that play a pivotal role in regulating cell growth, differentiation, angiogenesis, and tissue repair. These receptors are integral components of numerous physiological and pathological processes, making them key players in various diseases, including cancer and skeletal disorders (Xie et al., 2020; Ornitz & Itoh, 2015). In this blog, we will explore the intricate world of FGFRs, delving into their structure, functions in health and disease, and their significance in drug discovery.

FGFRs Blog Image

Understanding Fibroblast Growth Factor Receptors

FGFRs comprise a family of four highly conserved receptors: FGFR1, FGFR2, FGFR3, and FGFR4. Each receptor is activated by fibroblast growth factors (FGFs), a large family of signaling proteins that bind to FGFRs in conjunction with heparan sulfate proteoglycans (HSPGs) as cofactors (Ornitz & Itoh, 2015). Upon ligand binding, FGFRs undergo dimerization and autophosphorylation, leading to the activation of downstream signaling pathways such as the Ras/MAPK, PI3K/AKT, and PLCγ pathways (Turner & Grose, 2010). These signaling cascades are essential for cellular proliferation, survival, migration, and differentiation.

FGFRs exhibit distinct tissue distribution and functional specificity. For example, FGFR1 and FGFR2 are widely expressed in developmental and adult tissues, while FGFR3 plays a crucial role in skeletal development, and FGFR4 is primarily involved in liver metabolism and muscle function. Dysregulation of these receptors due to mutations, overexpression, or aberrant signaling can lead to severe pathological conditions (Babina & Turner, 2017).

Fibroblast Growth Factor Receptors in Disease

FGFRs have been implicated in a variety of diseases, particularly cancer. Aberrant FGFR signaling, resulting from gene amplification, mutations, or translocations, can drive oncogenesis by promoting uncontrolled cell proliferation and survival (Babina & Turner, 2017). FGFR1 amplification is commonly observed in breast and lung cancers, while FGFR2 mutations are linked to gastric and endometrial cancers. FGFR3 mutations are frequently associated with bladder and urothelial carcinomas, whereas FGFR4 overexpression has been linked to hepatocellular carcinoma (Helsten et al., 2016).

Beyond cancer, FGFR mutations contribute to skeletal disorders such as achondroplasia and thanatophoric dysplasia, both caused by activating mutations in FGFR3 that lead to impaired bone growth (Ornitz & Itoh, 2015). Additionally, FGFR signaling plays a role in metabolic diseases, wound healing, and cardiovascular disorders, further highlighting its importance in human health.

Given their involvement in various diseases, FGFRs are attractive targets for therapeutic intervention. FGFR inhibitors, including small-molecule tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and ligand traps, are being developed to selectively block aberrant FGFR signaling and restore normal cellular function (Porta et al., 2017).

Fibroblast Growth Factor Receptors in Drug Discovery

The central role of FGFRs in disease makes them promising targets for drug development. Several FGFR-targeted therapies have been approved or are under clinical investigation:

  • FGFR inhibitors: Small-molecule TKIs selectively inhibit FGFR activity, preventing tumor growth (Porta et al., 2017).
  • Monoclonal antibodies: These target specific FGFRs to block ligand binding and receptor activation.
  • FGF ligand traps: Designed to sequester FGFs, preventing them from interacting with FGFRs.
  • Combination therapies: FGFR inhibitors are being tested in combination with immunotherapy and chemotherapy to enhance treatment efficacy.

Selectivity in drug targeting is crucial to minimizing off-target effects. Advanced drug discovery efforts focus on developing highly specific inhibitors that target only dysregulated FGFRs while preserving normal physiological functions (Babina & Turner, 2017). Innovations in precision medicine and biomarker-driven therapies are further refining FGFR-targeted approaches to improve clinical outcomes.

Screening Against the Fibroblast Growth Factor Receptor Family

Screening a potential drug compound across all FGFR receptors — FGFR1, FGFR2, FGFR3, and FGFR4 — offers several advantages. It helps assess selectivity, ensuring the compound targets the intended receptor while minimizing off-target effects (Porta et al., 2017). This is particularly important since different FGFR inhibitors are used for specific cancers, like FGFR1 and FGFR2 inhibitors for breast or gastric cancers, and FGFR4 inhibitors for liver cancer. Comprehensive screening also identifies compounds with broader efficacy, which may be beneficial in diseases involving multiple FGFRs.

Cofactor receptors, particularly α-Klotho and β-Klotho, are essential to FGF endocrine signaling. These cofactors enhance receptor specificity by regulating the binding of fibroblast growth factors (FGFs) to their corresponding FGFRs (Kuro-o, 2019). α-Klotho is primarily associated with FGFR1 in kidney and parathyroid regulation, while β-Klotho partners with FGFR4 in liver metabolism. Screening compounds in the presence of these cofactors provides a clearer understanding of receptor activity and potential therapeutic effects.

Additionally, screening across all receptors can reveal potential toxicity risks. For example, unintended inhibition of FGFR3, crucial for bone development, could lead to skeletal issues (Ornitz & Itoh, 2015). Early detection of off-target effects allows researchers to refine compounds and improve safety. It also provides insights into the drug’s mechanism of action, uncovering unexpected interactions that may inform further drug development.

Furthermore, receptor-wide screening supports biomarker discovery and personalized medicine by linking receptor activity with patient-specific responses. This data can guide treatment decisions and optimize therapeutic outcomes. From a regulatory perspective, generating comprehensive receptor data strengthens the case for approval, ensuring both efficacy and safety. Ultimately, screening across all FGFR receptors, while considering the influence of α-Klotho and β-Klotho, is a strategic step in discovering targeted, effective therapies.

INDIGO’s FGFR Reporter Assays

Fibroblast growth factor receptors represent a compelling area of research in drug discovery due to their widespread implications in human health and disease. As scientists continue to unravel FGFR signaling complexities, novel therapeutics are likely to emerge, offering new hope for patients with FGFR-related conditions.

For researchers studying FGFRs, INDIGO Biosciences provides cell-based luciferase reporter assay kits for FGFR1/2, FGFR1c/αKlotho, FGFR1c/βKlotho, FGFR3, , FGFR4/αKlotho, and FGFR4/βKlotho. Our assays offer an all-inclusive luciferase reporter system, including optimized media, a reference activator, luciferase detection reagent, and a cell culture-ready assay plate. Additionally, INDIGO offers FGFR assay services, allowing researchers to screen compounds efficiently for their ability to regulate FGFR activity in agonist or antagonist mode using firefly luciferase reporter gene technology.

By utilizing INDIGO’s FGFR reporter assays, researchers can accelerate drug discovery efforts, identifying novel therapeutics for conditions involving FGFR dysregulation. Contact us today to learn more about our FGFR assay kits and screening capabilities!

Works Cited

Babina, I. S., & Turner, N. C. (2017). Advances and challenges in targeting FGFR signaling in cancer. Nature Reviews Cancer, 17(5), 318-332.

Helsten, T., Elkin, S., Arthur, E., Tomson, B. N., Carter, J., & Kurzrock, R. (2016). The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clinical Cancer Research, 22(1), 259-267.

Kuro-o, M. (2019). The Klotho proteins in health and disease. Nature Reviews Nephrology, 15(1), 27-44.

Ornitz, D. M., & Itoh, N. (2015). The fibroblast growth factor signaling pathway. Wiley Interdisciplinary Reviews: Developmental Biology, 4(3), 215-266.

Porta, R., Borea, R., Coelho, A., Khan, S., Araújo, A., Reclusa, P., & Fraga, C. A. (2017). FGFR a promising druggable target in cancer: Molecular biology and new drugs. Critical Reviews in Oncology/Hematology, 113, 256-267.

Turner, N., & Grose, R. (2010). Fibroblast growth factor signalling: from development to cancer. Nature Reviews Cancer, 10(2), 116-129.